Luigi Mangione, the 28-year-old charged in the fatal shooting of UnitedHealthcare CEO Brian Thompson, is expected to plead guilty Friday in Manhattan federal court in an apparent bid to avoid a life sentence.
The plea hearing, scheduled for Friday morning before U.S. District Judge Margaret Garnett, would resolve the federal case against Mangione on two remaining counts of stalking resulting in death, charges that still carry the possibility of life behind bars. Sources familiar with the matter cautioned that Mangione could still change his mind before or during the hearing, the New York Post reported.
A surprise hearing in Mangione's case on August 11 had already sparked speculation that a deal was in the works. If the plea goes through, it could reshape the broader legal landscape around the case, including the separate state murder prosecution brought by the Manhattan District Attorney's Office.
Mangione originally faced four federal counts, including a death-penalty-eligible charge of murder through use of a firearm. A federal judge threw out that count and one other earlier this year, citing "legal infirmities" in the government's case. The dismissal left prosecutors with two counts of stalking resulting in death, serious charges, but ones that removed the specter of capital punishment from the federal side.
Even so, a guilty plea on the remaining counts would leave sentencing in Judge Garnett's hands. Sources say Mangione would hope she imposes a lesser sentence than the maximum. The specific terms of any plea agreement have not been disclosed.
Federal prosecutors have maintained that Mangione plotted the killing to make a violent political statement. Bullet casings recovered at the scene had the words "delay" and "deny" etched into them, phrases that echo language critics have used to describe how insurers avoid paying out claims.
The federal plea carries consequences well beyond the federal courtroom. The Manhattan District Attorney's Office has claimed "primary jurisdiction" over the case, arguing it charged Mangione with murder first. A state trial is set to begin September 8.
But a federal guilty plea could trigger New York's double jeopardy protections, potentially crippling the DA's ability to prosecute Mangione on state charges for the same conduct. The DA's office could still push to take Mangione to trial if it objects to the terms of a federal deal, but the legal path forward would grow far more complicated.
Had no plea been reached, the federal trial was tentatively scheduled for early 2027.
Thompson, the CEO of UnitedHealthcare, was killed on a Manhattan sidewalk in December 2024. A five-day manhunt followed before police arrested Mangione at a McDonald's in Altoona, Pennsylvania. Mangione, a University of Pennsylvania graduate from a wealthy Maryland family, became the subject of intense public attention from the moment of his arrest.
The case drew extraordinary media interest. A state court approved 86 news organizations to cover the state trial, and proceedings have been closely watched at every stage.
Key questions remain unanswered. The precise sentencing range Mangione might face under a guilty plea has not been made public. Judge Garnett has not signaled any disposition. And the Manhattan DA's formal position on the plea terms, whether it has approved, objected, or is still weighing its options, is unclear.
Mangione's defense counsel has not been named publicly in connection with the expected plea, and federal prosecutors handling the case have not commented beyond what has been reported through sources.
If Mangione does plead guilty Friday, the man accused of gunning down a Fortune 500 CEO on a city sidewalk will have chosen a negotiated sentence over the risk of spending the rest of his life in a federal prison. Accountability is the point of the justice system, and the public deserves to know whether the terms of that accountability match the gravity of the crime.
